Rs.15 Lakh Costs Imposed in ‘ZERODOL’ Trademark Infringement Case

Rs.15 Lakh Costs Imposed in ‘ZERODOL’ Trademark Infringement Case. The Bombay High Court, while exercising jurisdiction through its Commercial Division, imposed costs of Rs.15 lakh on a pharmaceutical company for infringing the registered trademark “ZERODOL”, owned by IPCA Laboratories Limited.
The Court observed that the defendant had used a deceptively similar mark for medicinal products, which amounted to trademark infringement and passing off. Considering the sensitive nature of pharmaceutical goods, the Court held that such cases require strict judicial scrutiny to prevent confusion among consumers.
This judgment once again highlights the higher level of protection granted to pharmaceutical trademarks and the consistent approach of courts in discouraging dishonest adoption of marks in the healthcare sector.
Background of the Dispute
IPCA Laboratories Limited is a pharmaceutical company incorporated under the Companies Act and is the registered owner of the trademark “ZERODOL” in Class 5, which covers medicinal and pharmaceutical products.
The trademark was adopted in the early 1990s and has been continuously used in the market since 2003. Over time, IPCA introduced several pharmaceutical formulations under the “ZERODOL” brand, making it a well-known and distinctive mark in the pharmaceutical market.
The dispute arose when IPCA discovered that the defendant was manufacturing and selling a pain-relief medicine under the mark “ZEROVOL-P.” This mark was used for the same category of pharmaceutical products, raising concerns about possible confusion among consumers.
Proceedings Before the Court
After identifying the infringing product in the market, IPCA filed a commercial intellectual property suit before the Bombay High Court. The company sought a permanent injunction and other reliefs for trademark infringement and passing off.
At an early stage of the case, the Court granted ad-interim relief, restraining the defendant from using the impugned mark.
Despite receiving the summons, the defendant did not appear before the Court or file a written statement. As a result, the case proceeded as an undefended matter, and IPCA presented evidence to support its claims.
Evidence Presented by the Plaintiff
To support its case, IPCA relied on several documents and records, including:

Trademark registration certificates showing its legal rights over “ZERODOL.”

Sales invoices dating back to 2003 demonstrating continuous commercial use.

Records of promotional expenses and turnover showing goodwill and reputation in the market.

Samples and invoices of the defendant’s product sold under the mark “ZEROVOL-P.”

The plaintiff argued that the impugned mark was visually and phonetically similar to “ZERODOL” and that the defendant had adopted it dishonestly to take advantage of the reputation of the established brand.
Observations of the Court
After examining the evidence and submissions, the Court made the following key observations:

IPCA is the valid and registered proprietor of the trademark “ZERODOL.”

The trademark has been continuously and extensively used for pharmaceutical products for many years.

The mark has gained significant goodwill and recognition in the pharmaceutical market.

The defendant’s mark “ZEROVOL-P” is deceptively similar to “ZERODOL” when viewed as a whole, both visually and phonetically.

The defendant failed to provide any bona fide explanation for adopting the impugned mark.

The defendant adopted the mark after IPCA’s registration and long-standing use of “ZERODOL.”

The Court emphasised that in cases involving medicinal products, even a likelihood of confusion is sufficient to grant relief because such confusion may affect public health and safety.
Legal Provisions Involved
The Court considered the following statutory provisions while deciding the case:
Trade Marks Act, 1999

Section 28 – Grants exclusive rights to the registered proprietor to use the trademark and take action against infringement.

Section 29 – Defines infringement of a registered trademark, including the use of a deceptively similar mark for identical goods.

Section 134 – Provides jurisdiction to civil courts to hear trademark infringement and passing off suits.

Code of Civil Procedure, 1908

Section 35 (as amended by the Commercial Courts Act, 2015) – Allows courts to award costs in commercial disputes based on the conduct of the parties.

Commercial Courts Act, 2015

Section 16 – Applies the amended provisions of the CPC, including Section 35, to commercial disputes.

Relief Granted by the Court
Based on the findings, the Court passed a decree in favour of IPCA Laboratories Limited and granted a permanent injunction restraining the defendant from:

Using the mark “ZEROVOL-P” or any mark deceptively similar to “ZERODOL.”

Passing off its pharmaceutical products as those of IPCA.

The Court also directed the defendant to surrender all infringing goods, packaging materials, labels, and promotional items for destruction.
Court’s Decision on Costs
Although IPCA claimed damages, the Court noted that the plaintiff had not provided specific evidence to quantify financial loss.
However, while deciding the issue of costs under Section 35 of the CPC, the Court considered several factors:

The dishonest adoption of the infringing mark.

The defendant’s failure to appear before the Court despite proper service.

The fact that the dispute involved medicinal products, which require greater caution.

The need to discourage misuse of established pharmaceutical trademarks.

Considering these factors, the Court awarded Rs.15,00,000 as costs in favour of IPCA Laboratories Limited. The amount must be paid within eight weeks, failing which interest would apply.
Judicial Approach in Pharmaceutical Trademark Cases
The reasoning adopted by the Bombay High Court reflects the consistent approach followed by Indian courts in pharmaceutical trademark disputes.
Courts have repeatedly held that stricter standards must apply in such cases because confusion between medicinal trademarks can have serious consequences for patients.
Some key principles recognised by courts include:

Similarity must be assessed from the perspective of an average consumer with imperfect recollection.

Honest adoption is an important factor in determining infringement.

Courts may award deterrent costs in commercial intellectual property disputes where the conduct of the infringer justifies such action.

Conclusion
This judgment reinforces the strong protection given to registered trademarks in India, particularly in the pharmaceutical sector.
The decision makes it clear that courts will not only restrain infringing activity but may also impose significant costs where the infringement appears dishonest or where the defendant fails to contest the proceedings.
For pharmaceutical companies, the ruling serves as a reminder that proper trademark due diligence is essential before launching new products in the market. 
Frequently Asked Questions (FAQs)
Q1. What was the main issue in the ZERODOL trademark case?
Ans. The issue was whether the defendant’s use of the mark “ZEROVOL-P” for medicines infringed IPCA Laboratories’ registered trademark “ZERODOL” and amounted to passing off.
Q2. Why did the Court find trademark infringement?
Ans. The Court held that “ZEROVOL-P” was visually and phonetically similar to “ZERODOL” and was used for the same category of medicinal products.
Q3. Why do courts apply stricter rules in pharmaceutical trademark cases?
Ans. Because confusion between medicine names can affect public health and may lead to serious consequences.
Q4. Did the defendant contest the case?
Ans. No. The defendant did not appear before the Court or file a written statement, and the case proceeded as an undefended suit.
Q5. What relief did the Court grant?
Ans. The Court granted a permanent injunction, ordered destruction of infringing goods, and awarded Rs.15 lakh as costs to IPCA Laboratories.

The Bombay High Court, while exercising jurisdiction through its Commercial Division, imposed costs of Rs.15 lakh on a pharmaceutical company for infringing the registered trademark “ZERODOL”, owned by IPCA Laboratories Limited.

The Court observed that the defendant had used a deceptively similar mark for medicinal products, which amounted to trademark infringement and passing off. Considering the sensitive nature of pharmaceutical goods, the Court held that such cases require strict judicial scrutiny to prevent confusion among consumers.

This judgment once again highlights the higher level of protection granted to pharmaceutical trademarks and the consistent approach of courts in discouraging dishonest adoption of marks in the healthcare sector.

Background of the Dispute

IPCA Laboratories Limited is a pharmaceutical company incorporated under the Companies Act and is the registered owner of the trademark “ZERODOL” in Class 5, which covers medicinal and pharmaceutical products.

The trademark was adopted in the early 1990s and has been continuously used in the market since 2003. Over time, IPCA introduced several pharmaceutical formulations under the “ZERODOL” brand, making it a well-known and distinctive mark in the pharmaceutical market.

The dispute arose when IPCA discovered that the defendant was manufacturing and selling a pain-relief medicine under the mark “ZEROVOL-P.” This mark was used for the same category of pharmaceutical products, raising concerns about possible confusion among consumers.

Proceedings Before the Court

After identifying the infringing product in the market, IPCA filed a commercial intellectual property suit before the Bombay High Court. The company sought a permanent injunction and other reliefs for trademark infringement and passing off.

At an early stage of the case, the Court granted ad-interim relief, restraining the defendant from using the impugned mark.

Despite receiving the summons, the defendant did not appear before the Court or file a written statement. As a result, the case proceeded as an undefended matter, and IPCA presented evidence to support its claims.

Evidence Presented by the Plaintiff

To support its case, IPCA relied on several documents and records, including:

Trademark registration certificates showing its legal rights over “ZERODOL.”
Sales invoices dating back to 2003 demonstrating continuous commercial use.
Records of promotional expenses and turnover showing goodwill and reputation in the market.
Samples and invoices of the defendant’s product sold under the mark “ZEROVOL-P.”

Observations of the Court

After examining the evidence and submissions, the Court made the following key observations:

IPCA is the valid and registered proprietor of the trademark “ZERODOL.”
The trademark has been continuously and extensively used for pharmaceutical products for many years.
The mark has gained significant goodwill and recognition in the pharmaceutical market.
The defendant’s mark “ZEROVOL-P” is deceptively similar to “ZERODOL” when viewed as a whole, both visually and phonetically.
The defendant failed to provide any bona fide explanation for adopting the impugned mark.
The defendant adopted the mark after IPCA’s registration and long-standing use of “ZERODOL.”

The Court emphasised that in cases involving medicinal products, even a likelihood of confusion is sufficient to grant relief because such confusion may affect public health and safety.

Legal Provisions Involved

The Court considered the following statutory provisions while deciding the case:

Trade Marks Act, 1999

Section 28 – Grants exclusive rights to the registered proprietor to use the trademark and take action against infringement.
Section 29 – Defines infringement of a registered trademark, including the use of a deceptively similar mark for identical goods.
Section 134 – Provides jurisdiction to civil courts to hear trademark infringement and passing off suits.

Code of Civil Procedure, 1908

Section 35 (as amended by the Commercial Courts Act, 2015) – Allows courts to award costs in commercial disputes based on the conduct of the parties.

Commercial Courts Act, 2015

Section 16 – Applies the amended provisions of the CPC, including Section 35, to commercial disputes.

Relief Granted by the Court

Based on the findings, the Court passed a decree in favour of IPCA Laboratories Limited and granted a permanent injunction restraining the defendant from:

Using the mark “ZEROVOL-P” or any mark deceptively similar to “ZERODOL.”
Passing off its pharmaceutical products as those of IPCA.

The Court also directed the defendant to surrender all infringing goods, packaging materials, labels, and promotional items for destruction.

Court’s Decision on Costs

Although IPCA claimed damages, the Court noted that the plaintiff had not provided specific evidence to quantify financial loss.

However, while deciding the issue of costs under Section 35 of the CPC, the Court considered several factors:

The dishonest adoption of the infringing mark.
The defendant’s failure to appear before the Court despite proper service.
The fact that the dispute involved medicinal products, which require greater caution.
The need to discourage misuse of established pharmaceutical trademarks.

Considering these factors, the Court awarded Rs.15,00,000 as costs in favour of IPCA Laboratories Limited. The amount must be paid within eight weeks, failing which interest would apply.

Judicial Approach in Pharmaceutical Trademark Cases

The reasoning adopted by the Bombay High Court reflects the consistent approach followed by Indian courts in pharmaceutical trademark disputes.

Courts have repeatedly held that stricter standards must apply in such cases because confusion between medicinal trademarks can have serious consequences for patients.

Some key principles recognised by courts include:

Similarity must be assessed from the perspective of an average consumer with imperfect recollection.
Honest adoption is an important factor in determining infringement.
Courts may award deterrent costs in commercial intellectual property disputes where the conduct of the infringer justifies such action.

Conclusion

This judgment reinforces the strong protection given to registered trademarks in India, particularly in the pharmaceutical sector.

The decision makes it clear that courts will not only restrain infringing activity but may also impose significant costs where the infringement appears dishonest or where the defendant fails to contest the proceedings.

For pharmaceutical companies, the ruling serves as a reminder that proper trademark due diligence is essential before launching new products in the market.

Frequently Asked Questions (FAQs)

Q1. What was the main issue in the ZERODOL trademark case?

Ans. The issue was whether the defendant’s use of the mark “ZEROVOL-P” for medicines infringed IPCA Laboratories’ registered trademark “ZERODOL” and amounted to passing off.

Q2. Why did the Court find trademark infringement?

Ans. The Court held that “ZEROVOL-P” was visually and phonetically similar to “ZERODOL” and was used for the same category of medicinal products.

Q3. Why do courts apply stricter rules in pharmaceutical trademark cases?

Ans. Because confusion between medicine names can affect public health and may lead to serious consequences.

Q4. Did the defendant contest the case?

Ans. No. The defendant did not appear before the Court or file a written statement, and the case proceeded as an undefended suit.

Q5. What relief did the Court grant?

Ans. The Court granted a permanent injunction, ordered destruction of infringing goods, and awarded Rs.15 lakh as costs to IPCA Laboratories.